Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin

Arthritis Care and Research

Volumn 65, Issue 11, 2013, Pages 1813-1819

  Kim, Seoyoung C ^a   Landon, Joan E ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; DULOXETINE; GABAPENTIN; GASTROINTESTINAL AGENT; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG USE; FEMALE; FIBROMYALGIA; FOLLOW UP; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; RHEUMATOID ARTHRITIS; SLEEP DISORDER; SMOKING; UNITED STATES;

AMINES; AMITRIPTYLINE; ANALGESICS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE PROGRESSION; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME;

EID: 84887071245     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22071     Document Type: Article

References (23)

1. Wolfe F,. The epidemiology of fibromyalgia. J Musculoskeletal Pain 1993; 1: 137-48.
2. Wolfe F, Ross K, Anderson J, Russell IJ,. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995; 22: 151-6.
3. Wolfe F, Clauw DJ, FitzCharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600-10.
4. Clauw D, Crofford L,. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003; 17: 685-701.
5. Hauser W, Bernardy K, Uceyler N, Sommer C,. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain 2009; 145: 69-81.
6. Berger A, Dukes E, Martin S, Edelsberg J, Oster G,. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007; 61: 1498-508.
7. Gore M, Sadosky AB, Zlateva G, Clauw DJ,. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract 2009; 9: 363-74.
8. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ,. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30: 1318-25.
9. Boonen A, van den Heuvel R, van Tubergen A, Goossens M, Severens JL, van der Heijde D, et al. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 2005; 64: 396-402.
10. White L, Robinson R, Yu A, Kaltenboeck A, Samuels S, Mallett D, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain 2009; 10: 976-83.
11. Deyo R, Cherkin D, Ciol M,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
12. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ,. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64.
13. Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ,. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013; 22: 1-6.
14. Boulanger L, Wu N, Chen SY, Nagar S, Fraser K, Bernauer MJ, et al. Predictors of pain medication selection among patients diagnosed with fibromyalgia. Pain Pract 2012; 12: 266-75.
15. Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y,. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med Sci 2011; 124: 955-60.
16. Walker A,. Confounding by indication [editorial]. Epidemiology 1996; 7: 335-6.
17. Mellegers M, Furlan A, Mailis A,. Gabapentin for neuropathic pain: systematic review of controlled and uncontrolled literature. Clin J Pain 2001; 17: 284-95.
18. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ,. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; 3:CD007076.
19. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE Jr, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56: 1336-44.
20. Hauser W, Bernardy K, Uceyler N, Sommer C,. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301: 198-209.
21. Schneeweiss S, Avorn J,. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-37.
22. Hauser W, Jung E, Erbsloh-Moller B, Gesmann M, Kuhn-Becker H, Petermann F, et al. The German fibromyalgia consumer reports: a cross-sectional survey. BMC Musculoskelet Disord 2012; 13: 74.
23. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Hauser W,. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain 2013; 17: 581-6.